Herve C. Porchet
Pretoria, GT, South Africa
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 09, 2021
A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes.
Journal: Diabetes, obesity & metabolism
Published: November 11, 2019
A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env.
Journal: Clinical therapeutics
Published: February 15, 2019
A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti-HERV-W-Env monoclonal antibody.
Journal: Diabetes, obesity & metabolism
Published: March 29, 2018
A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
Journal: Multiple sclerosis and related disorders
Published: June 30, 2016
Treatment against human endogenous retrovirus: a possible personalized medicine approach for multiple sclerosis.
Journal: Molecular diagnosis & therapy
Published: September 18, 2015
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.
Journal: Journal of neuroimmunology
Published: March 19, 2015
Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.
Journal: mAbs
Published: November 27, 2014
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 13, 2014
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Journal: Clinical therapeutics
Published: October 18, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026